Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013

(2014) Daisuke Aoki   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH

Cancer of the corpus uteri

(2012) Frédéric Amant et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer

(2010) N Mori et al.   BRITISH JOURNAL OF CANCER

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

(2009) Sergio Pecorelli   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Surgically staged high-risk endometrial cancer: Randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy

(2008) Tapio Kuoppala et al.   GYNECOLOGIC ONCOLOGY

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

(2008) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY